

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)


PCT

(10) International Publication Number
WO 01/08603 A1

- (51) International Patent Classification⁷: **A61F 2/14**, 2/16, C08G 77/38, 77/388
- (74) Agent: **FREEHILLS CARTER SMITH BEADLE**; 101 Collins Street, Melbourne, Victoria 3000 (AU).
- (21) International Application Number: PCT/AU00/00915
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 2 August 2000 (02.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PQ 1978 2 August 1999 (02.08.1999) AU
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION** [AU/AU]; Limestone Avenue, Canberra, Australian Capital Territory 2612 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CLAYTON, Anthony, Brian** [AU/AU]; 2/25 Paddington Road, Oakleigh, Victoria 3166 (AU). **MEIJS, Gordon, Francis** [AU/AU]; 3 Henty Street, Murrumbeena, Victoria 3163 (AU).
- Published:**
— *With international search report.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



(54) Title: BIOMEDICAL COMPOSITIONS



WO 01/08603 A1

(57) Abstract: A method of preparing intraocular lenses *in situ* is disclosed. The method involves the injection of an unsaturated macromonomer of Formula (I). The macromonomer is then polymerised to give a polymer having an E modulus in the range 0.5 - 5 kPa.

BIOMEDICAL COMPOSITIONS

Technical Field of the Invention

This invention relates to ethylenically unsaturated macromonomers that are suitable for use as precursors for polymers in biomedical applications.

5 Background of the Invention

The use of polymeric prostheses and biomedical mouldings has grown rapidly in recent times. Such mouldings may be used for contact lenses or for specific ophthalmic purposes. For example, they may be used for intraocular lenses and eye bandages. They may also be used for surgical mouldings such as heart
10 valves and artificial arteries. Other applications include wound dressings, biomedical adhesives and tissue scaffolds. Use in drug delivery is a further application.

Diseases of the lens material of the eye are often in the form of cataracts. The ideal cataract procedure is considered to be one where the lens capsule bag is maintained with the cataractous lens material removed through a small opening in
15 the capsule. The residual lens epithelial cells are removed chemically and/or with ultrasound or lasers. A biocompatible material with appropriate optical clarity, refractive index and mechanical properties is inserted into the capsular bag to restore the qualities of the original crystalline lens. The desired refractive index is
20 1.41.

There have been recent advances in methods of inserting intraocular lens. For example, US Patent number 5,772,667 assigned to Pharmacia Lovision Inc, discloses a novel intraocular lens injector. This device compresses an intraocular lens by rolling the lens into a tight spiral. The device then injects the compressed
25 lens through a relatively small incision in the eye, approximately 2- 3 millimetres in length, resulting from a phacoemulsification procedure. The intraocular lens is inserted into a receiving channel of the injector device in an uncompressed state and is urged into a cylindrical passageway. As the intraocular lens advances into the cylindrical passageway, the lens rolls upon itself into a tightly rolled spiral within
30 the confines of the cylindrical passageway. An insertion rod is then inserted into an open end of the cylindrical passageway and advances the compressed lens down the

passageway. As the lens exits the passageway and enters the eye, the lens will expand back to its uncompressed state.

To avoid the need for such injection devices, it has been proposed that intraocular lenses be formed *in situ* after being injected as a liquid flowable form into the lens capsule bag. However, while this concept is attractive in that smaller incisions would be required, it raises further difficulties in that further chemical reactions are required to cure the injectable material and these are required to be not harmful to the patient. It is also a requirement that the chemical reactions can take place over a relatively short time under mild reaction conditions. It is desirable that the reaction is also not significantly inhibited by oxygen. A still further requirement is that no by-products or residues are produced that may have an adverse biological effect on the patient.

As adults age the accommodative power of the eye decreases leading to the onset of presbyopia. This age-related decrease in accommodative power is believed to be caused by a decrease in the elasticity of the lens material. This decrease is probably caused by cross-linking of the lens material. Thus the loss of accommodation results from a change in elasticity rather than a decrease in the action of the ciliary muscles. The replacement of the original lens with a synthetic polymer having the elasticity equivalent to the lens of a young adult offers the prospect of being able to use a surgical procedure to replace the need for glasses to correct presbyopia.

US Patent No. 5,079,319 assigned to Ciba-Geigy Corporation discloses vinyl unsaturated macromonomers that are prepared via a two stage process. In the first stage of this process copolymers are prepared by addition polymerisation of ethylenically unsaturated monomers. The monomers are selected such that the polymer chain includes polysiloxane units pendant from a carbon backbone. Ethylenic unsaturation is introduced into the copolymer in the second stage by reaction of an active hydrogen in the polymer chain with an unsaturated isocyanate. The unsaturated macromonomer so formed may be subsequently crosslinked in a mould to form contact lenses. This invention is described as being an improvement over US Patent No. 4,605,712 which has a common assignee. The improvement is


described as being the ability to introduce higher concentrations of siloxane groups without the problems of phase-separation and opacity associated with the compositions of 4,605,712. Patent number 5,079,319 asserts that addition polymerisation in the first stage leads to more random introduction of siloxane groups and thus the avoidance of large incompatible domains.

Silicones containing pendant (meth)acrylic or (meth)acrylamide groups are particularly suitable for rapid crosslinking using radical photoinitiating systems. US Patent No. 4,563,539 assigned to Dow Corning Corporation, discloses the synthesis of acrylofunctional siloxanes.

International Publication No. WO99/47185 in the name of Pharmacia & Upjohn Groningen BV proposes intraocular compositions comprising aqueous dispersions of polymerisable microgels. This application relies upon the microgel structure to obtain the rapid crosslinking required for intraocular lens procedures. The invention of this application is distinguished from this invention as it uses oligomers and solution polymers. The citation claims that it is not possible to achieve the required balance of speed of crosslinking, refractive index and mechanical properties necessary for intraocular procedures with such polymers.

Summary Of The Invention

This invention provides in one form an ethylenically unsaturated macromonomer comprising units of Formula I:



where L is a linker group

Z is an ethylenically unsaturated free radical polymerisable group

y is ≥ 2

x is ≥ 5

and wherein the ethylenically unsaturated groups are provided by (meth)acrylamide moieties.

The linker group, L, functions as a spacing group which allows the required ethylenic unsaturated group Z to be attached to the copolymer backbone. It may be
5 a linear, branched or cyclic hydro carbyl chain. It may contain hetero atoms as well as carbonyl and other substituted atoms.

In an alternative form this invention provides an ethylenically unsaturated macromonomer comprising units of Formula I wherein the molecular weight of the macromonomer is in the range 3,000 – 80,000, and wherein the ethylenically
10 unsaturated groups are provided by (meth)acrylamide, (meth)acrylate and styrenic moieties.

In a further alternative form this invention provides an ethylenically unsaturated macromonomer comprising units of Formula I wherein the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt, and more
15 preferably 1,000 – 10,000 cSt and after polymerisation has an E modulus in the range 0.01 – 100 kPa, preferably 0.1 – 10kPa and more preferably 0.5 – 5kPa.

In an alternative embodiment this invention provides polymers for biomedical application wherein polymers are polymerised from macromonomers as defined above.

In a still further alternative form this invention provides a method of
20 preparing intraocular lenses *in situ* by injecting a flowable macromonomer composition of Formula I into a lens capsule bag where:

L is a linker group;

Z is an ethylenically unsaturated free radical polymerisable group;

25 y is ≥ 2

and x is ≥ 5


and wherein the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt, and more preferably 1,000 – 10,000 cSt and polymerising the macromonomer to provide a polymer having an E modulus in the range 0.01 – 100 kPa, preferably
30 0.1 – 10kPa and more preferably 0.5 – 5kPa.


In a further embodiment this invention provides a method of treating presbyopia by making an incision into the cornea of a patient, removing the lens material and injecting a flowable macromonomer composition of Formula I where the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt, and more preferably 1,000 – 10,000 cSt and polymerising the macromonomer to provide a polymer having an E modulus in the range 0.01 – 100 kPa, preferably 0.1 – 10kPa and more preferably 0.5 – 5kPa.

Detailed Description Of The Invention

The most effective process for producing the preferred (meth)acrylamide-based macromonomers involves the attachment of acrylamide functional groups to poly(dimethylsiloxane-co-aminoalkylsiloxane) copolymers by reaction with 2-vinyl-4,4-dimethylazlactone in solution as set out below in the scheme of reaction.

However, treatment of the poly(dimethylsiloxane-co-aminoalkylsiloxane) copolymers with acryloyl chloride or other such reagents is an alternative means of synthesis.





acrylamide-functionalised
polydimethyl-aminopropylsiloxane
copolymer

5 The macromonomers set out in the above scheme of reaction as well as in Formula I are preferably random copolymers. However block type copolymers also fall within the scope of the present invention.

While generally the compositions of the present invention do not usually involve the use of other macromonomers, these may be optionally included. This
10 can be an advantage when the refractive index or viscosity needs to be adjusted. Preferably the compositions comprise at least 50%, more preferably at least 80%, by weight of macromonomers as defined in the present invention.

The macromonomers of this invention may be polymerised by free radical
15 polymerisation to form crosslinked or cured polymers. The mechanical and optical properties of the polymers are preferably matched to those of the natural biological material. In the case of lens material for the eye the refractive index should be close to 1.41. The modulus (E) of the polymer is measured by a Bohlin controlled stress rheometer in the range 0.01 – 100 kPa, preferably 0.1 – 10 kPa and most preferably
20 0.5 – 5kPa. The E modulus is influenced by the number of ethylenically unsaturated groups per macromonomer and also the spacing of the ethylenically unsaturated groups. Generally as the number of ethylenically unsaturated groups

per macromonomer molecule increases or the spacing between ethylenically unsaturated groups decreases the elasticity of the cured polymer decreases.

The crosslinking process is preferably carried out in such a way that the macromonomer comprising cross-linkable groups is free or essentially free from undesired constituents, in particular from monomeric, oligomeric or polymeric starting compounds used for the preparation of the cross-linkable macromonomer. The polymer product should also be free from by-products formed during the preparation of the crosslinked polymer. The macromonomer is preferably used without the addition of a comonomer although this is allowed.

In the case of photo cross-linking, it is expedient to add an initiator which is capable of initiating free-radical crosslinking. Examples thereof are known to the person skilled in the art; suitable photoinitiators which may be mentioned specifically are benzoin, benzoin ethers, such as benzoin methyl ether, benzoin ethyl ether, benzoin isopropyl ether and benzoin phenyl ether, and benzoin acetate; acetophenones, such as acetophenone, 2,2-dimethoxyacetophenone and 1,1-dichloroacetophenone; benzil, benzil ketals, such as benzil dimethyl ketal and benzil diethyl ketal, camphorquinone, anthraquinones, such as 2-methylantraquinone, 2-ethylantraquinone, 2-tert-butylantraquinone, 1-chloroanthraquinone and 2-amylantraquinone; furthermore triphenylphosphine, benzoylphosphine oxides, for example 2,4,6-trimethylbenzoyl-diphenylphosphine oxide, benzophenones, such as benzophenone and 4,4'-bis(N,N'-dimethylamino)benzophenone; thioxanthenes and xanthenes; acridine derivatives; phenazine derivatives; quinoxaline derivatives and 1-phenyl-1,2-propanedione 2-O-benzoyl oxime; 1-aminophenyl ketones and 1-hydroxyphenyl ketones, such as 1-hydroxycyclohexylphenyl ketone, phenyl 1-hydroxyisopropyl ketone, 4-isopropylphenyl 1-hydroxyisopropyl 1-hydroxyisopropyl ketone, 2-hydroxy-1-[4-(2-hydroxyethoxy)phenyl]-2-methylpropan-1-one, 1-phenyl-2-hydroxy-2-methylpropan-1-one, and 2,2-dimethoxy-1,2-diphenylethanone, all of which are known compounds.

Particularly suitable photoinitiators, which are usually used with UV lamps as light sources, are acetophenones, such as 2,2-dialkoxybenzophenones and

hydroxyphenyl ketones, in particular the initiators known under the trade names IRGACURE[®]819 and IRGACURE[®]184. A particularly preferred photoinitiator is IRGACURE[®] 651.

Another class of photoinitiators usually employed when argon ion lasers are used are benzil ketals, for example benzil dimethyl ketal.

The photoinitiators are added in effective amounts, expediently in amounts from about 0.05 to about 2.0% by weight, in particular from 0.1 to 0.5% by weight, based on the total amount of cross-linkable macromonomer.

The resultant cross-linkable macromonomer can be introduced into a mould using methods known per se, such as, in particular, conventional metering, for example dropwise. Alternatively, the macromonomers may be cured *in situ*, as for example in the case of an injectable lens. In this case the macromonomer is cured or crosslinked in the lens capsule after injection.

The cross-linkable macromonomers which are suitable in accordance with the invention can be crosslinked by irradiation with ionising or actinic radiation, for example electron beams, X-rays, UV or VIS light, ie electromagnetic radiation or particle radiation having a wavelength in the range from about 280 to 650 nm. Also suitable are UV lamps, He/Dc, argon ion or nitrogen or metal vapour or NdYAG laser beams with multiplied frequency. It is known to the person skilled in the art that each selected light source requires selection and, if necessary, sensitisation of the suitable photoinitiator. It has been recognised that in most cases the depth of penetration of the radiation into the cross-linkable macromonomer and the rate of curing are in direct correlation with the absorption coefficient and concentration of the photoinitiator. As well as photoinitiation, redox and thermal initiators may be used satisfactorily.

If desired, the crosslinking can also be initiated thermally. It should be emphasised that the crosslinking can take place in a very short time in accordance with the invention, for example, in less than five minutes, preferably in less than one minute, more preferably in less than 30 seconds. It will be appreciated that while the macromonomers of this invention may be used alone to form the lenses and other biocompatible materials, other materials may also be present. For

example, diluents may be present as well as other monomers including other macromonomers. When used as an injectable material the macromonomers should have a viscosity in the range 1,000 – 20,000 cSt and more preferably 1,000 – 10,000 cSt at 25°C. Instruments such as the Brookfield rheometer or the Bohlin controlled stress rheometer may be conveniently used for measurement.

The invention will be further described by reference to the following examples where all parts are expressed as parts by weight.

Example 1

This example illustrates the preparation of an acrylamide macromonomer.

10 An acrylamidoorganosilicon macromonomer of Formula I, where $y = 3$, $x = 60$, and having a molecular weight in the range from 4,000 to 5,000, containing three acrylamido radicals A, having the formula $-C(O)-C(CH_3)_2-NHC(O)CH=CH_2$ was prepared as follows:



Into a 25ml flask equipped with a stirrer bar and containing 10ml dry dichloromethane is placed 2.4g of a commercially available aminopropylmethylsiloxane-dimethylsiloxane copolymer (available from Gelest, Inc., Tullytown, PA as Product AMS-162). To this is added 0.23g of distilled 2-vinyl-4,4-dimethylazlactone. The reaction mixture is stirred for 18 hours, after which the infra red spectrum is recorded to confirm complete consumption of the vinylazlactone. Dichloromethane solvent is then removed *in vacuo* to yield a macromonomer of viscosity 250 centiStokes (cSt).

Example 2

This example illustrates the preparation of a crosslinked polymer using the macromonomer prepared in Example 1.

The acrylamide-functionalised siloxane and Irgacure 651 photoinitiator (Ciba Speciality Chemicals) were separately dissolved in chloroform in the proportions given below. The solutions were combined and the chloroform was removed *in*

vacuo. The following example was placed into polypropylene moulds (designed to give a flat polymeric disc of 20.7mm diameter and 1.0mm depth) and polymerised for ten minutes under irradiation from a 365nm UV lamp. All parts are by weight.

Macromonomer of Formula I (x = 60, y = 3)	100 parts
Irgacure 651	0.3 parts

5

After polymerisation was complete, a transparent, rubbery polymer disc was removed from the moulds. The shear modulus of the polymer was measured with a Bohlin controlled stress rheometer (CS-10) as 220 kPa.

Example 3

10

This example illustrates that the synthetic procedure outlined in Example 1 may be extended to other amino group containing polydimethylsiloxane copolymers.

Macro monomer	Mole % amino groups	Molecular weight	Percent azlactone substitution of amino groups	Shear Modulus (kPa) after polymerisation	Viscosity (cSt)	r.i.
2A ¹	2 - 4	28,000-32,000	47%	85	14,600	1.4132
2B ¹	2- 4	28,000 - 32,000	25%	2.5	250	1.4239

15

1. Prepared from Aminoethylaminopropyl Methylsiloxane-Dimethylsiloxane Copolymer (Gelest Systems, Inc. Product AMS-233).

Macromonomers 2A and 2B were prepared in a similar fashion to macromonomer 1.

Example 4


This example illustrates the preparation of cured polymers from macromonomers prepared according to Example 3.

Macromonomers 2A and 2B were placed into polypropylene moulds and polymerised for ten minutes under irradiation from a 365nm UV lamp. 100 parts
5 Macromonomer and 0.3 parts Irgacure 651 photoinitiator were used in both examples. The difference in shear moduli for examples 2A and 2B shows that the mechanical properties of the polymer can be varied as desired by changing the degree of acrylamide substitution.

Example 5

10 This example illustrates the preparation of a macromonomer where the ethylenically unsaturated groups are provided by acrylate moieties and the polymerisation of this macromonomer to a polymer.

A silicone acrylate compound of Formula II, where the average value of $x = 790$, and the average value of $y = 60$, and the molecular weight of the
15 macromonomer is 62,000 containing an average of 60 acrylate radicals, A, having the formula $-C(=O)-O-CH=CH_2$, was prepared as follows:



20 In a 250ml round-bottom flask equipped with a reflux condenser and drying tube, methylhydrosiloxane-dimethylsiloxane copolymer (available from Gelest, Inc., Tullytown, PA as Product HMS-064) (20.03g, 18.91 mmol SiH groups) and allyl chloride (Aldrich, 1.45g, 18.9 mmol) were dissolved in 50ml dry toluene and then 95 microlitres of a 0.02M solution of hexachloroplatinic acid in isopropanol
25 was added. The reaction mixture was then stirred for 18 h at 80°C. Consumption of the silicone hydride (SiH) groups was verified by treating an aliquot of the reaction mixture with ethanolic KOH solution – no hydrogen evolution was observed.

The reaction mixture was then cooled to 5°C and butylated hydroxytoluene
30 (25mg) and dry pyridine (1.5g, 18.96mmol) were added. A solution of 2-hydroxyethyl acrylate (2.196g, 18.90mmol) in 10ml dry toluene was then added


dropwise at such a rate so as to maintain the reaction temperature below 5°C. The macromonomer was washed twice with methanol (100ml) and then left for four days in a dark environment. Irgacure 651 photoinitiator (Ciba Speciality Chemicals) was dissolved in dry toluene and combined with the acrylate-
 5 functionalised siloxane in dry toluene to give a concentration of photoinitiator to macromonomer identical to that for Example 4.

The formulation (viscosity 7,3000 cSt) was then placed into polypropylene moulds designed to give a flat polymeric disc (refractive index 1.4107) of 20.7mm diameter and 1.0mm depth, (obtained from CIBA Vision, Atlanta) and polymerised
 10 for ten minutes under irradiation from a 365nm UV lamp. After polymerisation was complete, a transparent, rubbery polymer disc (refractive index 1.4107) was removed from the mould. The shear modulus of the polymer was measured with a Bohlin controlled stress rheometer (CS-10) as 44.5 kPa.

Example 6

15 This example illustrates the preparation of a macromonomer where the ethylenically unsaturated groups are provided by methacrylate moieties and the polymerisation of this macromonomer to a polymer.

A silicone methacrylate compound of Formula III, where the average value of $x = 730$, and the average value of $y = 7$, and the molecular weight of the
 20 macromonomer is 55,000 containing an average of 7 methacrylate radicals, A, having the formula $-C(=O)-O-(CH_3)CH=CH_2$, was prepared as follows:



25 Into a 50ml flask equipped with a stirrer bar and containing 20ml dry toluene is placed 2.6543g (0.36 mmol SiH groups) of a commercially available methylhydrosiloxane-dimethylsiloxane copolymer (available from Gelest, Inc., Tullytown, PA as Product HMS-013) and 0.2g (1.59 mmol) of allyl methacrylate. 100 microlitres of a 0.02M solution of hexachloroplatinic acid in isopropanol is
 30 then added. The reaction mixture is stirred for 72 hours, after which the 1H NMR spectrum is recorded to confirm complete reaction of the silicone hydride group

($\delta = 4.7\text{ppm}$).

The methacrylate-functionalised siloxane and Irgacure 651 photoinitiator (Ciba Specialty Chemicals) (in proportions identical to that used in Example 4) were separately dissolved in toluene. The solutions were combined and the toluene
5 removed *in vacuo*, to yield a macromonomer of viscosity 3,300 cSt.

The formulation was then placed into polypropylene moulds (designed to give a flat polymeric disc of 20.7 mm diameter and 1.0mm depth, obtained from CIBA Vision, Atlanta) and polymerised for ten minutes under irradiation from a 365nm UV lamp. After polymerisation was complete, a transparent, rubbery
10 polymer disc (refractive index 1.4086) was removed from the mould. The shear modulus of the polymer was measured with a Bohlin controlled stress rheometer (CS-10) as 22.5 kPa.

Example 7

This example illustrates the *in vivo* use of macromonomers according to this
15 invention as intraocular lenses.

After initial softening by techniques such as phacoemulsification, endolenticular fragmentation, laser phacolysis, the existing lens material of a patient is removed *via* aspiration through a small (less than 1.2mm, but preferably equal to or less than 0.5mm) capsulorhexis at the periphery of the lens, with minimal
20 damage to the capsule and peripheral tissue. The interior of the capsular bag is then cleaned and aspirated to remove cellular debris which may contribute to opacification of the posterior capsule subsequent to surgery – a number of viscoelastic fluids e.g. hyaluronic acid may be used to flush the lens capsule. Other techniques (e.g. photodynamic therapy) may be used at this time to provide an
25 additional means of decreasing the incidence of posterior capsule opacification.

The macromonomer from Example 1 that is to form the substitute lens material is then introduced into the capsular bag through the capsulorhexis via a narrow gauge cannula. Optionally, an additional valve device may be positioned on the exterior of the empty lens capsule to enable injection of the substitute lens
30 material without leakage prior to cure of the material. After refilling of the lens

capsule, the material is cured by UV irradiation. Other means including, but not limited to visible irradiation, thermal or redox reaction could also have been used.

The incision in the cornea is sutured and allowed to heal.


5

10

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An ethylenically unsaturated macromonomer comprising units of Formula I:

5



where L is a linker group

Z is an ethylenically unsaturated free radical polymerizable group

10

y is ≥ 2

x is ≥ 5

and wherein the ethylenically unsaturated groups are provided by (meth)acrylamide moieties.

- 15 2. An ethylenically unsaturated macromonomer comprising units of Formula I wherein the molecular weight of the macromonomer is in the range 3,000 – 80,000, and wherein the ethylenically unsaturated groups are provided by (meth)acrylamides, (meth)acrylate and styrenic moieties.

- 20 3. An ethylenically unsaturated macromonomer comprising units of Formula I and as defined in claim 1 wherein the ethylenic unsaturation is introduced by 2-vinyl-4,4-dimethylazlactone.

4. An ethylenically unsaturated macromonomer as defined in any one of claims
25 1 – 3 wherein the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt.

5. An ethylenically unsaturated macromonomer as defined in any one of claims 1 to 4 wherein after polymerisation the polymer has an E modulus in the range 0.01 – 100 kPa.
- 5 6. An ethylenically unsaturated macromonomer as defined in claim 4 or claim 5 wherein the macromonomer has a viscosity at 25°C in the range 1,000 to 10,000 cSt.
7. An ethylenically unsaturated macromonomer as defined in any one of claims 10 4 to 6 wherein the polymer has an E modulus of 0.1 – 10 kPa.
8. An ethylenically unsaturated macromonomer as defined in claim 7 wherein the polymer has an E modulus of 0.5 – 5 kPa.
- 15 9. An ethylenically unsaturated macromonomer as defined in any one of claims 1 to 8 wherein after polymerisation the polymer has a refractive index in the range 1.39 – 1.44.
- 10 10. A method of preparing intraocular lenses *in situ* by injecting a flowable macromonomer composition of Formula I into a lens capsule bag where:
- L is a linker group;
- Z is an ethylenically unsaturated free radical polymerisable group;
- y is ≥ 2
- and x is ≥ 5
- 25 and wherein the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt, and polymerising the macromonomer to provide a polymer having an E modulus in the range 0.01 – 100 kPa, preferably 0.1 – 10kPa and more preferably 0.5 – 5kPa.
- 30 11. A method of treating presbyopia by making an incision into the cornea of a patient, removing the lens material and injecting a flowable macromonomer

composition of Formula I as defined in claim 1 or claim 2 where the macromonomer has a viscosity at 25°C in the range 1,000 – 20,000 cSt, and more preferably 1,000 – 10,000 cSt and polymerising the macromonomer to provide a polymer having an E modulus in the range 0.01 – 100 kPa, preferably 0.1 – 10kPa
5 and more preferably 0.5 – 5kPa.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00915

A. CLASSIFICATION OF SUBJECT MATTER																	
Int. Cl. ⁷ : A61F 2/14, 2/16, C08G 77/38, 77/388																	
According to International Patent Classification (IPC) or to both national classification and IPC																	
B. FIELDS SEARCHED																	
Minimum documentation searched (classification system followed by classification symbols) IPC A61F 2/14, 2/16, C08G 77/38, 77/388																	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC AS ABOVE																	
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DERWENT WPAT AND JPAT: ACRYLAMIDE POLYSILOXANE PRESBYOPIA INTRAOCULAR LENS																	
C. DOCUMENTS CONSIDERED TO BE RELEVANT																	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
A	US 5 610 257 A (HERVE RICHARD ET AL) 11 MARCH 1997 See column 5, formula 1; example 1; claims 1-23	1-11															
A	US 5 346 946 A (YASUHIRO YOKOYAMA ET AL) 13 SEPTEMBER 1994 See columns 1-5; claims 1-7.	1-11															
A	EP 578 087 A (MENICON CO., LTD) 12 JANUARY 1994 See pages 1-7; claims 1-13.	1-11															
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																	
<p>* Special categories of cited documents:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%;">"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td style="width: 30%;">"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> <td style="width: 40%;"></td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> <td></td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> <td></td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family		"P" document published prior to the international filing date but later than the priority date claimed		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family																
"P" document published prior to the international filing date but later than the priority date claimed																	
Date of the actual completion of the international search 18 August 2000		Date of mailing of the international search report 31 AUG 2000															
Name and mailing address of the ISA/AU/AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer B CROUCH Telephone No : (02) 6283 2060															

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/AU00/00915

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US	5 610 257	EP	711779	AT	162792	AU	34236/95
		BR	9504902	CA	2162330	CN	1135487
		DE	69501541	FR	2726562	HU	9503194
		JP	8208668	KR	171687	PL	311263
		RU	2133119	US	5714134	ZA	9508886
US	5 346 946	JP	6121826				
EP	578087	AU	41545/93	CA	2099326	JP	6070946

END OF ANNEX